Knowledge hub

Last April Oxipit took the medical imaging world by storm. The medical imaging company received a CE Class IIb certificate for the first autonomous AI imaging application ChestLink. Learn about the team who made this innovation possible.

A study led by Louis Lind Plesner, MD comparing the performance of four commercial AI CXR tools was published in the Radiology Journal, with Oxipit ChestEye among the ones tested. The study evaluated AI algorithm performance for detecting airspace disease, pneumothorax, and pleural effusion.

A study by researchers at Mahajan Imaging and CARPL.ai was conducted to evaluate the performance of diagnostic AI tools for quality assurance. The study found that nearly 1% of chest radiographs included clinically significant diagnostic mistakes, which were identified by Oxipit Quality AI software. The study was presented at the ECR2023 annual meeting earlier in March.

An AI tool can accurately identify normal and abnormal chest X-rays in a clinical setting, according to a study published in Radiology. The tool may greatly alleviate the heavy workload experienced by radiologists globally.  

At the European Congress of Radiology in Vienna Oxipit announced that its diagnostic AI solutions will be available on the CARPL platform. CARPL platform users will have access to the full Oxipit AI product portfolio: ChestLink for healthy patient report automation, Quality - for real-time quality assurance and ChestEye - for preliminary reports. The move further builds on Oxipit strategy to increase global reach of company’s products.

The regulatory approval paves the way for ChestEye deployments in the Brazilian market. The application is already cleared for use in Europe and Australia. The Brazilian Health Regulatory Agency’s approval is one of Oxipit steps to increase global reach for company products.

AI medical imaging company Oxipit closed a $4.9M funding round led by Taiwania Capital, Practica Capital, and Coinvest Capital. Angel investors also participated in this round. The funding will help Oxipit advance its development of autonomous AI medical imaging applications and support market expansion into new geographic regions, with particular focus on the United Kingdom.

AI medical imaging company Oxipit expanded its ChestEye Quality product with quality assurance support for musculoskeletal X-rays, mammography images and CT scans. The new imaging modalities will follow the same AI-powered double reading workflow as with chest X-ray images. New Quality features will be showcased at RSNA 2022 annual meeting later this month.

Kaunas city polyclinic introduced Oxipit ChestLink AI application in their preventive health check up workflow. With ChestLink, which can automatically identify normal chest X-rays, healthy patients can be instantly sent home after the examination, without the need to wait for the study report at the polyclinic. Operating with 99.9% sensitivity, ChestLink can automatically report on 26% of all X-ray studies at Kaunas city polyclinic.

The new partnership aims to mitigate the risk associated with missed findings in CT medical imaging studies. The collaboration will combine Oxipit’s ChestEye Quality and contextflow’s SEARCH Lung CT products to identify missed findings in CT scans in near-real time. ECR 2022 will offer the first preview of the combined solution, and the first installation will be deployed at Leiden University Medical Center.